RxDoctor Payments Data

Soka Yu

Adult Health · New York, NYNPI 1073989869

Payments from drug & device makers

$10,252in general payments, 2019–2025

Across 243 payments — averaging $42.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • Neurelis, Inc.$2K
  • UCB, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • SK Life Science, Inc.$1K
  • AstraZeneca$372
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$2,11021%
  • Food & beverage$8,10979%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,252 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$17,603
Medicare patients
70
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam156$232,557
XcopriCenobamate168$209,979
EpidiolexCannabidiol (Cbd)47$186,261
Lamictal XrLamotrigine43$155,650
OnfiClobazam48$98,348
AptiomEslicarbazepine Acetate41$87,986
Keppra XrLevetiracetam35$55,433
VimpatLacosamide24$53,112
Oxtellar XrOxcarbazepine28$47,674
Lamotrigine ErLamotrigine153$40,504
LamictalLamotrigine28$32,155
Clobazam272$30,767
NayzilamMidazolam16$26,267
FycompaPerampanel18$23,927
Lacosamide296$23,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$1,645$311,936196 claims
SK Life Science, Inc.Xcopri$1,125$209,979168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →